Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study.

Lawrence Blonde Julio Rosenstock Juan Pablo FriasAndreas L BirkenfeldElisabeth NiemoellerElisabeth SouhamiChen JiStephano Del Prato Vanita R Aroda

Published in: Diabetes care (2021)

The efficacy and safety of iGlarLixi at the end of the 26-week randomized treatment period was maintained over the 26-week extension period in the LixiLan-G trial.

Keyphrases

placebo controlled
type diabetes
phase iii
phase ii
double blind
open label
clinical trial
study protocol
cardiovascular disease
randomized controlled trial
metabolic syndrome
adipose tissue
gestational age
weight loss
replacement therapy
preterm birth